GT200900189A - Compuesto de [1,2,3]-benzotriazinona-3-sustituido para mejorar las respuestas sinapticas glutamatérgicas. - Google Patents
Compuesto de [1,2,3]-benzotriazinona-3-sustituido para mejorar las respuestas sinapticas glutamatérgicas.Info
- Publication number
- GT200900189A GT200900189A GT200900189A GT200900189A GT200900189A GT 200900189 A GT200900189 A GT 200900189A GT 200900189 A GT200900189 A GT 200900189A GT 200900189 A GT200900189 A GT 200900189A GT 200900189 A GT200900189 A GT 200900189A
- Authority
- GT
- Guatemala
- Prior art keywords
- composite
- replaced
- benzotriazinona
- glutamateric
- answers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
ESTA INVENCIÓN SE REFIERE A LA PREVENCIÓN Y TRATAMIENTO DE INSUFICIENCIA CEREBRAL, INCLUYEDO INCREMENTO DEL FUNCIONAMIENTO DE RECEPTORES EN LA SINAPSIS EN LAS REDES CEREBRALES RESPONSABLES DEL COMPORTAMIENTOS DE ORDEN SUPERIOR. ESTAS REDES CEREBRALES ESTÁN IMPLICADAS EN LAS CAPACIDADES COGNITIVAS RELACIONADAS CON LA ALTERACIÓN DE LA MEMORIA, TALCOMO SE OBSERVA EN UNA VARIEDAD DE DEMENCIAS, Y EN DESEQUILIBRIOS DE LA ACTIVIDAD NEURONAL ENTRE DIFERENTES REGIONES CEREBRALES, COMO SE SUGIERE EN TRASTORNOS TALES COMO LA ENFERMEDAD DE PARKINSON, ESQUIZOFRENIA Y TRASTORNOS AFECTIVOS. EN UN ASPECTO PARTICULAR, LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE 1,2,3 BENZOTRIAZONA 3 SUSTITUIDO PARA EL TRATAMIENTO DE DICHAS CONDICIONES, Y A MÉTODOS PARA UTILIZAR ESTE COMPUESTO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87850307P | 2007-01-03 | 2007-01-03 | |
US92143307P | 2007-04-02 | 2007-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200900189A true GT200900189A (es) | 2011-08-02 |
Family
ID=39608956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900189A GT200900189A (es) | 2007-01-03 | 2009-07-02 | Compuesto de [1,2,3]-benzotriazinona-3-sustituido para mejorar las respuestas sinapticas glutamatérgicas. |
Country Status (38)
Country | Link |
---|---|
US (1) | US8173644B2 (es) |
EP (1) | EP2144506B1 (es) |
JP (1) | JP5139446B2 (es) |
CN (1) | CN101616592B (es) |
AP (1) | AP2502A (es) |
AR (1) | AR064740A1 (es) |
AT (1) | ATE527269T1 (es) |
AU (1) | AU2007342365B2 (es) |
BR (1) | BRPI0720749A2 (es) |
CA (1) | CA2674460C (es) |
CR (1) | CR10906A (es) |
CU (1) | CU23804B7 (es) |
CY (1) | CY1112493T1 (es) |
DK (1) | DK2144506T3 (es) |
EA (1) | EA017437B1 (es) |
EC (1) | ECSP099499A (es) |
ES (1) | ES2374995T3 (es) |
GE (1) | GEP20125438B (es) |
GT (1) | GT200900189A (es) |
HK (1) | HK1140105A1 (es) |
HN (1) | HN2009001268A (es) |
HR (1) | HRP20110970T1 (es) |
IL (1) | IL199651A (es) |
MA (1) | MA31160B1 (es) |
ME (1) | ME00819B (es) |
MX (1) | MX2009007242A (es) |
MY (1) | MY154877A (es) |
NI (1) | NI200900131A (es) |
NZ (1) | NZ578293A (es) |
PL (1) | PL2144506T3 (es) |
PT (1) | PT2144506E (es) |
RS (1) | RS52108B (es) |
SG (1) | SG163545A1 (es) |
SI (1) | SI2144506T1 (es) |
SV (1) | SV2009003322A (es) |
TN (1) | TN2009000277A1 (es) |
WO (1) | WO2008085506A1 (es) |
ZA (1) | ZA200904826B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2114158B1 (en) * | 2007-01-03 | 2012-08-08 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
KR101599661B1 (ko) | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
US8168632B2 (en) | 2007-08-10 | 2012-05-01 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for the treatment of respiratory disorders |
SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
US9242938B2 (en) | 2011-11-22 | 2016-01-26 | Beijing Medisan Technology Co., Ltd | Glycine reuptake inhibitor and use thereof |
FR3019464B1 (fr) | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
FR3034019B1 (fr) * | 2015-03-26 | 2017-03-17 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent |
MX2017016875A (es) | 2015-06-26 | 2018-04-24 | Takeda Pharmaceuticals Co | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1. |
CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3723436A (en) * | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
FR2597103B1 (fr) * | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
ATE215079T1 (de) | 1992-07-24 | 2002-04-15 | Univ California | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
DK0709384T3 (da) * | 1994-10-31 | 1999-08-23 | Merck Patent Gmbh | Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder |
US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
AU4416197A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
EP1071426A2 (en) | 1998-02-18 | 2001-01-31 | Neurosearch A/S | Novel compounds and their use as positive ampa receptor modulators |
US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
NZ532368A (en) * | 2001-11-26 | 2006-10-27 | Cortex Pharma Inc | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
JP2003238555A (ja) * | 2002-02-20 | 2003-08-27 | Sumitomo Pharmaceut Co Ltd | 細胞死抑制剤 |
AUPS255202A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
JP2006516283A (ja) * | 2003-01-13 | 2006-06-29 | コーテックス ファーマシューティカルズ, インコーポレイテッド | 睡眠不足とストレスに起因する知覚衰退の処置方法 |
GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
EP2114158B1 (en) * | 2007-01-03 | 2012-08-08 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
KR101599661B1 (ko) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
US20100267728A1 (en) * | 2007-09-20 | 2010-10-21 | Cortex Pharmaceuticals, Inc. | 3-substituted-1,2,3-triazin-4-one's and 3 substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2007
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/me unknown
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 RS RS20110587A patent/RS52108B/en unknown
- 2007-12-28 CA CA2674460A patent/CA2674460C/en not_active Expired - Fee Related
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/en active Application Filing
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
- 2007-12-28 US US12/448,784 patent/US8173644B2/en not_active Expired - Fee Related
- 2007-12-28 EP EP07868093A patent/EP2144506B1/en active Active
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
-
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
-
2010
- 2010-06-29 HK HK10106349.3A patent/HK1140105A1/xx not_active IP Right Cessation
-
2011
- 2011-12-23 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200900189A (es) | Compuesto de [1,2,3]-benzotriazinona-3-sustituido para mejorar las respuestas sinapticas glutamatérgicas. | |
ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
CR10913A (es) | Compuestos de benzotriazinone para mejorar las respuestas sinapticas glutamatergicas | |
CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
EP4324527A3 (en) | Formulations of enzalutamide | |
CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
ECSP12011692A (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
CL2007003879A1 (es) | Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson. | |
CL2008002246A1 (es) | Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion. | |
CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
CO6660435A2 (es) | Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado | |
CO6470823A2 (es) | Piperidinas sustituidas | |
AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
TN2015000032A1 (en) | Inhibitors of beta-secretase | |
CR20160215A (es) | Espiro-oxazolonas | |
CL2018001633A1 (es) | Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos | |
CR20170195A (es) | Espiro-tiazolonas | |
WO2014052398A8 (en) | Inhibitors of beta-secretase | |
UA93306C2 (ru) | Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций | |
CL2012000650A1 (es) | Compuestos derivados de dihidro- benzocicloalquiloximetil- oxazolopirimidonas sustituidas, moduladores alosterocos de receptores metabortropicos de glutamato ( mglur); composicion famaceutica que los comprende; y uso para el tratamiento y/o prevencion de enfermedades asociadas del snc, como ansiedad, migraña, dolor, entre otras. | |
CR20120083A (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurologicos |